Rok Čivljak

Prof. Dr. Rok Čivljak

School of Medicine, University of Zagreb, Zagreb, Zagreb, Grad, Croatia
+1
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2023 in Intensive Care Medicine
Verified
Journal Article
Open access
PDF file
Ignacio Martin-LoechesIgnacio Martin-Loeches
Ignacio Martin-Loeches
LRLuis Felipe Reyes
Luis Felipe Reyes
SNSaad Nseir
Saad Nseir
OROtavio Ranzani
Otavio Ranzani
PPPedro Povoa
Pedro Povoa
APAngelo Pezzi
Angelo Pezzi
Purpose Lower respiratory tract infections (LRTI) are the most frequent infectious complication in patients admitted to the intensive care unit (ICU). We aim to report the clinical characteristics of ICU-admitted patients due to nosocomial LRTI and to describe their microbiology and clinical outcomes. Methods A prospective observational study was conducted in 13 countries over two continents from 9th May 2016 until 16th August 2019. Characteristics and outcomes of ventilator-associated pneumonia (VAP), ventilator-associated tracheobronchitis (VAT), ICU hospital-acquired pneumonia (ICU-HAP), HAP that required invasive ventilation (VHAP), and HAP in patients transferred to the ICU without invasive mechanical ventilation were collected. The clinical diagnosis and treatments were per clinical practice and not per protocol. Descriptive statistics were used to compare the study groups. Results 1060 patients with LRTI (72.5% male sex, median age 64 [50–74] years) were included in the study; 160 (15.1%) developed VAT, 556 (52.5%) VAP, 98 (9.2%) ICU-HAP, 152 (14.3%) HAP, and 94 (8.9%) VHAP. Patients with VHAP had higher serum procalcitonin (PCT) and Sequential Organ Failure Assessment (SOFA) scores. Patients with VAP or VHAP developed acute kidney injury, acute respiratory distress syndrome, multiple organ failure, or septic shock more often. One thousand eight patients had microbiological samples, and 711 (70.5%) had etiological microbiology identified. The most common microorganisms were Pseudomonas aeruginosa (18.4%) and Klebsiella spp (14.4%). In 382 patients (36%), the causative pathogen shows some antimicrobial resistance pattern. ICU, hospital and 28-day mortality were 30.8%, 37.5% and 27.5%, respectively. Patients with VHAP had the highest ICU, in-hospital and 28-day mortality rates. Conclusion VHAP patients presented the highest mortality among those admitted to the ICU. Multidrug-resistant pathogens frequently cause nosocomial LRTI in this multinational cohort study.

24 June 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
MKMichael Kunze
Michael Kunze
Pavle BanovicPavle Banovic
Pavle Banovic
PBPetra Bogovič
Petra Bogovič
VBVioleta Tincuta Briciu
Violeta Tincuta Briciu
Rok ČivljakRok Čivljak
Rok Čivljak
WEWilhelm Erber
Wilhelm Erber
There has been an increase in reported TBE cases in Europe since 2015, reaching a peak in some countries in 2020, highlighting the need for better management of TBE risk in Europe. TBE surveillance is currently limited, in part, due to varying diagnostic guidelines, access to testing, and awareness of TBE. Consequently, TBE prevalence is underestimated and vaccination recommendations inadequate. TBE vaccine uptake is unsatisfactory in many TBE-endemic European countries. This review summarizes the findings of a scientific workshop of experts to improve TBE surveillance and vaccine uptake in Europe. Strategies to improve TBE surveillance and vaccine uptake should focus on: aligning diagnostic criteria and testing across Europe; expanding current vaccine recommendations and reducing their complexity; and increasing public education of the potential risks posed by TBEV infection.

14 September 2021 in Life
Verified
Journal Article
Open access
PDF file
IFIva Fercek
Iva Fercek
Liborija Lugović-MihićLiborija Lugović-Mihić
Liborija Lugović-Mihić
ATArjana Tambic
Arjana Tambic
DĆDiana Ćesić
Diana Ćesić
AGAna Gverić Grginić
Ana Gverić Grginić
Rok ČivljakRok Čivljak
Rok Čivljak
Many relatively common chronic inflammatory skin diseases manifest on the face (seborrheic dermatitis, rosacea, acne, perioral/periorificial dermatitis, periocular dermatitis, etc.), thereby significantly impairing patient appearance and quality of life. Given the yet unexplained pathogenesis and numerous factors involved, these diseases often present therapeutic challenges. The term “microbiome” comprises the totality of microorganisms (microbiota), their genomes, and environmental factors in a particular environment. Changes in human skin microbiota composition and/or functionality are believed to trigger immune dysregulation, and consequently an inflammatory response, thereby playing a potentially significant role in the clinical manifestations and treatment of these diseases. Although cultivation methods have traditionally been used in studies of bacterial microbiome species, a large number of bacterial strains cannot be grown in the laboratory. Since standard culture-dependent methods detect fewer than 1% of all bacterial species, a metagenomic approach could be used to detect bacteria that cannot be cultivated. The skin microbiome exhibits spatial distribution associated with the microenvironment (sebaceous, moist, and dry areas). However, although disturbance of the skin microbiome can lead to a number of pathological conditions and diseases, it is still not clear whether skin diseases result from change in the microbiome or cause such a change. Thus far, the skin microbiome has been studied in atopic dermatitis, seborrheic dermatitis, psoriasis, acne, and rosacea. Studies on the possible association between changes in the microbiome and their association with skin diseases have improved the understanding of disease development, diagnostics, and therapeutics. The identification of the bacterial markers associated with particular inflammatory skin diseases would significantly accelerate the diagnostics and reduce treatment costs. Microbiota research and determination could facilitate the identification of potential causes of skin diseases that cannot be detected by simpler methods, thereby contributing to the design and development of more effective therapies.

30 January 2015 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
HEHakan Erdem
Hakan Erdem
DODerya Ozturk-Engin
Derya Ozturk-Engin
HTHulya Tireli
Hulya Tireli
GKGamze Kilicoglu
Gamze Kilicoglu
SDSylviane Defres
Sylviane Defres
HVHaluk Vahaboglu
Haluk Vahaboglu

1 October 2014 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
PDF file
HEHakan Erdem
Hakan Erdem
DOD. Ozturk-Engin
D. Ozturk-Engin
NENazif Elaldi
Nazif Elaldi
SGS. Gulsun
S. Gulsun
GSG. Sengoz
G. Sengoz
CAC. Agalar
C. Agalar

16 December 2013 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
Rok ČivljakRok Čivljak
Rok Čivljak
MGMaddalena Giannella
Maddalena Giannella
Stefano Di BellaStefano Di Bella
Stefano Di Bella
Nicola PetrosilloNicola Petrosillo
Nicola Petrosillo
The widespread use of antibiotics has been associated with the emergence of antimicrobial resistance among bacteria. 'ESKAPE' (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acintobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) pathogens play a major role in the rapidly changing scenario of antimicrobial resistance in the 21st century. Chloramphenicol is a broad spectrum antibiotic that was abandoned in developed countries due to its association with fatal aplastic anemia. However, it is still widely used in the developing world. In light of the emerging problem of multi-drug resistant pathogens, its role should be reassessed. Our paper reviews in vitro data on the activity of chloramphenicol against ESKAPE pathogens. Susceptibility patterns for Gram-positives were good, although less favorable for Gram-negatives. However, in combination with colistin, chloramphenicol was found to have synergistic activity. The risk-benefit related to chloramphenicol toxicity has not been analyzed. Therefore, extra precautions should be taken when prescribing this agent.